Wai Yuen Tong Medicine Holdings Limited EBIT

The latest EBIT for 0897.HK is $-39M as of March 2026. That compares with $130M in the prior-year period — down 129.5% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Wai Yuen Tong Medicine Holdings Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 0897.HK's EBIT moved from $130M to $-39M — a 129.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Wai Yuen Tong Medicine Holdings Limited's operating scale or balance-sheet position.

Against its sector companies, 0897.HK currently prints $-39M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Wai Yuen Tong Medicine Holdings Limited's growth, margins, and balance sheet.

A EBIT figure of $-39M for 0897.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 0897.HK's EBIT ($-39M), review year-over-year change from $130M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.